Revvity (RVTY) Q1 2026 Earnings Transcript

Motley Fool Transcribing, The Motley Fool

Tue, May 5, 2026 astatine 10:44 AM CDT 44 min read

Image source: The Motley Fool.

DATE

Tuesday, May 5, 2026 astatine 7:30 a.m. ET

CALL PARTICIPANTS

• President and Chief Executive Officer — Prahlad Singh

• Chief Financial Officer — Maxwell Krakowiak

• Vice President, Investor Relations — Stephen Willoughby

Full Conference Call Transcript

Prahlad Singh: Thank you, Steve, and bully morning, everyone. I person respective important developments to sermon today. First, I'm truly excited to study that Revvity delivered beardown archetypal 4th results with 3% full institution integrated growth, demonstrating the resilience and spot of our business. Our adjusted operating margins came successful astatine 23.6%, which was supra our 23% outlook. These results are a bully commencement to the twelvemonth and presumption america good to execute our afloat twelvemonth expectations, which Max volition update you connected successful a bit.

The better-than-anticipated gross and borderline show successful the 4th led to our adjusted net per stock successful the 4th being $1.06, which was solidly supra the $1.02 to the $1.04 outlook that was implied successful our guidance. I adjacent privation to item a transformative strategical determination we person made that volition accelerate our maturation trajectory, amended our fiscal illustration and let for adjacent much focused investments. Following an extended review, we person decided to divest our immunodiagnostics concern successful China, which represented astir 6% of full institution gross past year. This determination reflects our committedness to focusing resources wherever we tin make the highest returns for shareholders going forward.

The wellness attraction marketplace successful China, peculiarly diagnostics, has faced persistent policy-induced headwinds that person dramatically impacted some lawsuit request and pricing dynamics. Unfortunately, we spot these challenges continuing implicit the mean term. To support our presumption successful this space, it would necessitate america to marque important investments, including afloat localizing manufacturing, proviso chains and regulatory capabilities. This would necessitate meaningful superior allocation, resulting successful a deprioritization of different higher imaginable instrumentality initiatives disposable to us. Rather than deploying worldly dollars and absorption attraction to code the structural challenges successful the China immunodiagnostics market, we are choosing to ore our efforts connected concern areas wherever we person wide competitory advantages and spot steadfast maturation trajectories.

This is an intentional strategical allocation of our resources towards higher worth opportunities that volition thrust and further amended our aboriginal performance. In fact, this selective attack is being validated by our show successful different parts of our China business. For example, our Life Sciences concern successful the region, which was larger successful implicit gross dollars past twelvemonth than the immunodiagnostics concern we volition beryllium divesting continued to execute good with reagents increasing solidly supra our wide reagents show past year.